An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha

New York Presbyterian Hospital, New York

Johns Hopkins Oncology Center, Baltimore

H. Lee Moffet Cancer Center & Research Institute/Univ of South Florida, Tampa

University of Michigan, Ann Arbor

Wayne State University/Kamanos Cancer Center, Detroit

Northwestern Univ meical School/Robert H. Lurie Comprehensive Cancer Center, Chicago

C/O V. Ward - Washington Univ. school of Medicine, St Louis

MD Anderson Cancer Center, University of Texas, Houston

UCLA Medical Center, Los Angeles

Oregon Health & sciences University, Portland

Dana Faber Cancer Institute, Boston

Novartis Investigative Site, Lille

Novartis Investigative Site, Pessac

Novartis Investigative Site, Poitiers

Novartis Investigative Site, Frankfurt

Novartis Investigative Site, Leipzig

Novartis Investigative Site, Mainz

Novartis Investigative Site, Mannheim

Novartis Investigative Site, Bologna

Novartis Investigative Site, Milan

Novartis Investigative Site, Monza

Novartis Investigative Site, Orbassano

Novartis Investigative Site, Pavia

Novartis Investigative Site, Rome

Novartis Investigative Site, Udine

Novartis Investigative Site, Basel

Novartis Investigative Site, London

Novartis Investigative Site, Newcastle upon Tyne